Six Injections of Modified Adjuvanted PQ Grass Is Effective and Well-Tolerated in a Pivotal Phase III Trial.

Specifically, in this study, the key secondary endpoint IgG4 demonstrated a highly statistically significant 6‐fold increase after treatment with PQ Grass compared to placebo and was confirmed by significant reduction in the grass‐specific IgE/IgG4 ratio, which indicates a positive trend towards induction and prevalence of blocking IgG4 antibodies over grass‐specific IgE.

also in 11,005 other papers

The primary endpoint EAACI‐CSMS 0–6 (peak GPS) demonstrated a highly significant and clinically meaningful point difference of PQ Grass over placebo of −0.27 points (95% CI: −0.42 to −0.12), corresponding to a relative difference of −20.3% ( p = 0.0005).

also in 132,142 other papers